Sequential paclitaxel followed by tegafur and uracil (UFT) or S-1 versus UFT or S-1 monotherapy as adjuvant chemotherapy for T4a/b gastric cancer (SAMIT): a phase 3 factorial randomised controlled trial
- 18 June 2014
- journal article
- research article
- Published by Elsevier BV in The Lancet Oncology
- Vol. 15 (8), 886-893
- https://doi.org/10.1016/s1470-2045(14)70025-7
Abstract
No abstract availableKeywords
This publication has 41 references indexed in Scilit:
- Standing the test of time: targeting thymidylate biosynthesis in cancer therapyNature Reviews Clinical Oncology, 2014
- Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trialsThe Lancet, 2012
- Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trialThe Lancet, 2012
- Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008International Journal of Cancer, 2010
- Overall survival benefit for weekly vs. three-weekly taxanes regimens in advanced breast cancer: A meta-analysisCancer Treatment Reviews, 2010
- Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trialThe Lancet, 2009
- Adjuvant Chemotherapy for Gastric Cancer with S-1, an Oral FluoropyrimidineNew England Journal of Medicine, 2007
- Perioperative Chemotherapy versus Surgery Alone for Resectable Gastroesophageal CancerNew England Journal of Medicine, 2006
- Efficacy of Adjuvant Chemotherapy Using Oral Fluorinated Pyrimidines for Curatively Resected Gastric Cancer: A Meta-Analysis of Centrally Randomized Controlled Clinical Trials in JapanJournal of Chemotherapy, 2006
- Randomized Phase III Study of Docetaxel Compared With Paclitaxel in Metastatic Breast CancerJournal of Clinical Oncology, 2005